It inhibits tumor growth and CD44-dependent antiangiogenic activity. It also targeting CD44-positive BCSCs, it also inhibits migration, invasion, and formation of mammospheres resistant to endocrine therapy. It reduces lung metastases in an in vivo model by downregulating DLL4 and Notch4. Here, CD44 is linked to neoplasm.